TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03206242

Intervention type: OTHER
Intervention: Physiotherapy
Description: Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.

Intervention type: OTHER
Intervention: Physiotherapy
Description: Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.

Intervention type: OTHER
Intervention: Physiotherapy
Description: Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
Study: NCT01518426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Recording (Emotiv)
Description: Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)
Study: NCT00789958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
Study: NCT00980980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine bath and nasal mupirocin
Description: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine bath and nasal mupirocin
Description: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
Study: NCT04073940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Ballet Program
Description: All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
Study: NCT03290248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244 suspension
Description: B244 suspension in 30ml/bottle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, 30ml/bottle
Study: NCT00561886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: One inhalation of 24µg Formoterol
Study: NCT02482519

Intervention type: OTHER
Group type: OTHER
Intervention: High calorie diet
Description: High calorie diet for 10 days

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting
Description: 10 day fast
Study: NCT02306577

Intervention type: DRUG
Intervention: STRIBILD
Description: Taking oral 1 STRIBILD tablet once a day for 48 weeks
Study: NCT00004124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT03887624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: 1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
Study: NCT03096002

Intervention type: BEHAVIORAL
Intervention: Lifestyle change
Description: The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
Study: NCT04353921

Intervention type: OTHER
Intervention: No intervention will be administered as part of this study.
Description: No intervention will be administered as part of this study.

Intervention type: OTHER
Intervention: No intervention will be administered as part of this study.
Description: No intervention will be administered as part of this study.
Study: NCT02508688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic diaphragmatic repair
Description: patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
Study: NCT03887624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
Study: NCT03546907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440340
Description: Pharmaceutical form: Solution for injection; Route of administration: SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection; Route of administration: SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study: NCT03127410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar traction
Description: Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
Study: NCT02223455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Hygiene Signs
Description: Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Hygiene Signs
Description: Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hand Hygiene Signs
Description: Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
Study: NCT00516633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra information and support
Description: Four group discussions with parents in close connection to diagnosing the children
Study: NCT02375958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA062
Study: NCT03081533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circle Dance Program (CircleCare)
Description: Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
Study: NCT01007539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CDP-choline
Description: The subjects will be given 1g citicoline twice daily for a total of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fructose)
Description: The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
Study: NCT01945528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-guided tenotomy with PRP
Description: Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure
Study: NCT02857114

Intervention type: OTHER
Group type: OTHER
Intervention: massage
Study: NCT01941524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa instillation
Description: aEEG and NIRS monitoring during poractant alfa instilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beractant instillation
Description: aEEG and NRs monitoring during beractant instillation
Study: NCT01945528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-guided tenotomy with lidocaine
Description: Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
Study: NCT01595607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Treatment
Description: Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Treatment
Description: Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
Study: NCT02516046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: positron emission tomography (PET) scan
Study: NCT01725711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPRA Implant System
Study: NCT03546907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study: NCT03736954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive suggestion
Description: humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
Study: NCT03546907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any short-acting β agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Study: NCT01999855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phoniatric tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phoniatric tests
Study: NCT05049837

Intervention type: OTHER
Intervention: Group Specific Aim 1
Description: 600 cases: two normal and two tumor formalin-fixed tissue samples
Study: NCT03546907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any short-acting β agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Study: NCT05049837

Intervention type: OTHER
Intervention: Group Specific Aim 2
Description: 600 cases: two normal and two tumor formalin-fixed tissue samples.
Study: NCT00983593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging
Description: 16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
Study: NCT02137265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Clomiphene citrate 50 mg orally daily
Study: NCT05049837

Intervention type: OTHER
Intervention: Group Specific Aim 3
Description: 600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples

Intervention type: OTHER
Intervention: Group Specific Aim 4
Description: 600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
Study: NCT02137265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill every other day
Study: NCT00255125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Supplement
Description: Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Study: NCT05049837

Intervention type: OTHER
Intervention: Group Specific Aim 5
Description: 600 cases; two normal and two tumor formalin-fixed tissue samples

Intervention type: OTHER
Intervention: Group Specific Aim 6
Description: 210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study: NCT03427905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipoaspiration
Description: Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation
Description: Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
Study: NCT03150108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 25 mcg rhPTH(1-84) SC injection
Study: NCT04560855

Intervention type: DEVICE
Intervention: Connected devices measurements
Description: The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
Study: NCT03150108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 50 mcg rhPTH(1-84) SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 100 mcg rhPTH(1-84) SC injection
Study: NCT02205606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 5mg
Description: P.O.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 10mg
Description: P.O.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 20mg
Description: P.O.
Study: NCT03396848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAReClinic
Description: Online clinic with educational modules
Study: NCT04080258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Description: The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Therapy (LTT)
Description: The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
Study: NCT01790529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
Study: NCT03597100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala TWO
Description: Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
Study: NCT02620761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Description: Randomized to receive Fenoldopam or 0.9%NS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NS
Description: Randomized to receive Fenoldopam or 0.9%NS
Study: NCT03696862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free gingival graft
Description: Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
Study: NCT04388839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: IV over 60 minutes with dosing ranging from 220mg to 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV over 60 minutes with dosing ranging from 220mg to 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV over 60 minutes with dosing ranging from 220mg to 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV over 60 minutes with dosing ranging from 220mg to 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV push over 6-10 minutes with dosing ranging from 4mg-25mg